Alere has announced a voluntary withdrawal of the Alere INRatio and INRatio 2 PT/INR Monitoring System. Alere has announced a voluntary withdrawal of the Alere INRatio and INRatio 2 PT/INR Monitoring ...
FREMONT, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- CoaguSense, Inc., a subsidiary of i-SENS (KOSDAQ:099190), today announced that it has received approval for the sale of the Coag-Sense ® PT/INR ...
New Orleans, LA - Results of a new randomized comparison shows that weekly home INR monitoring is safe but did not reduce stroke, major bleeds, or death when compared with monthly clinic-based INR ...
Alere has issued a voluntary correction to users of the Alere INRatio and INRatio 2 PT/INR Monitor system of certain medical conditions that should not be tested with the system (INRatio Monitor ...
Exemption of the system from virtually all CLIA rules gives more labs access to connectivity and data management capabilities for monitoring patients on warfarin therapy INDIANAPOLIS, Oct. 1, 2012 ...
MINNEAPOLIS, July 11, 2023 /PRNewswire/ -- ARKRAY USA, Inc., a leader in diabetes and resident care solutions to long-term care facilities, announced today the launch of Assure PT Care PT/INR ...
WALTHAM, Mass., Dec. 8, 2014 /PRNewswire/ -- Alere Inc. has initiated a voluntary correction to inform U.S. users of the Alere INRatio(R) and INRatio(R)2 PT/INR Monitor system of certain medical ...
FREMONT, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- CoaguSense, Inc., a subsidiary of i-SENS (KOSDAQ:099190), today announced that it has received approval for the sale of the Coag-Sense ® PT/INR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback